Friday, December 23, 2011
After transforming the drug-development world with its focus on diseases with only a few thousand patients, BioMarin is using that same model to tackle cancer in subsets of patients. So instead of working on a drug aimed at the full population of ovarian cancer patients — many of whom won’t benefit from the treatment — it is zeroing in on a much smaller group with a specific genetic mutation.
“It turns cancer into an orphan disorder,” said BioMarin CEO Jean-Jacques Bienaime.
(San Francisco Business Times subscription required.)